《藍籌業績》中國生物製藥(01177.HK)全年純利25.44億人幣跌82.6% 派末期息6港仙
中國生物製藥(01177.HK)公佈截至去年12月底止全年業績,營業額287.8億元人民幣(下同),按年升7.1%。純利25.44億元,按年跌82.6%;每股盈利13.66分。派末期息6港仙,上年同期派末期息4港仙。連同已派發中期股息每股6港仙,全年合共派發股息每股12港仙。
期內,經調整非《香港財務報告準則》歸母淨利潤約29.9億元,按年增長16.4%。毛利升6.8%至229.8億元。
公司去年新產品銷售收入按年增長19.8%至125.1億元,佔集團總收入比例從2021年約38.9%上升至去年約43.5%。抗腫瘤用藥收入增長14.3%至91.9億元,佔總收入增至31.9%。創新藥收入升20%至67.5億元,佔總收入升至23.5%。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.